Wepredic

Wepredic is a privately held biotech group that leverages over 30 years of collective expertise in biological and chemical systems to serve the pharmaceutical, cosmetic, and chemical industries. Its business model combines platform technology (proprietary cell-based assays like HepaRG®), diagnostic tools, and contract research services to help clients evaluate compound toxicity and pharmacokinetics. With over 1,000 customers globally, the company is in a revenue-generating, commercial stage, focusing on innovation and digital service expansion to maintain its market position.

Integrated chemo-biological models for safety assessment, centered on the proprietary HepaRG® human hepatocyte cell line for toxicology and ADME studies, complemented by custom chemical probe synthesis and full-service safety testing.

Wepredic competes in the preclinical CRO and in vitro toxicology market with large CROs (e.g., Charles River, Labcorp), specialized toxicology assay providers, and developers of alternative cell models (e.g., stem cell-derived hepatocytes). Its differentiation lies in the integrated offering of a proprietary, validated cell system, chemical tools, and assessment services under one group.